The $25 price target has become a focal point in the ClearPoint Neuro investment narrative because it represents the low end of the current Wall Street consensus. Stifel Nicolaus, which initiated coverage and subsequently raised its target, maintains a $25 objective. Meanwhile, B. Riley Securities and Lake Street each carry $30 targets. With the stock trading near $14.60 after a steep decline from its 52-week high of $30.10 reached in October 2025, the question of whether CLPT can reclaim $25 is central to the risk-reward calculus for potential investors. The level also aligns with fair-value estimates produced by several independent research firms using discounted cash flow (DCF) models that incorporate the company's biologics pipeline.
ClearPoint Neuro, Inc. is a commercial-stage medical device company headquartered in Solana Beach, California, that develops and commercializes precision navigation platforms for minimally invasive neurosurgical procedures. Its flagship ClearPoint Neuro Navigation System, which has FDA clearance and CE marking, enables surgeons to perform brain biopsies, deep brain stimulation electrode placements, laser catheter insertions, and direct drug infusions under real-time MRI guidance. The company's SmartFlow cannula is co-labeled with several partner drug products targeting conditions such as Huntington's disease. With the acquisition of IRRAS in late 2025, ClearPoint expanded into the intracranial fluid management market through the IRRAflow Active Fluid Exchange System. The company currently serves more than 175 activated clinical centers globally and partners with over 60 biopharma organizations in preclinical and clinical-stage programs.
ClearPoint Neuro reported first-quarter 2026 revenue of $12.1 million, representing 43% overall growth year-over-year, with full-year 2026 guidance set between $52 million and $56 million. Gross margins improved to 64%, reflecting increased operating leverage and favorable product mix. However, the company remains unprofitable, posting a GAAP net loss of $29.07 million over the trailing twelve months and an EPS of negative $1.01. Cash and cash equivalents stood at $35.6 million as of March 31, 2026, down from $45.9 million at year-end 2025. The premium valuation, with a price-to-sales ratio near 10x trailing revenue, reflects market expectations for future growth rather than current financial performance. The company's beta of approximately 1.24 indicates above-average volatility relative to the broader market.
The single most powerful near-term catalyst is uniQure's progress with AMT-130, a gene therapy candidate for Huntington's disease that uses ClearPoint's navigation platform and SmartFlow cannula for direct brain delivery. In mid-2026, the FDA agreed that three-year Phase I/II data could serve as the primary basis for a Biologics License Application (BLA) seeking accelerated approval, with uniQure planning to file during the third quarter of 2026. A potential approval in mid-2027 would convert ClearPoint's platform from a clinical-trial tool into a commercial drug-delivery system, unlocking a new recurring revenue stream. Beyond AMT-130, the company's biologics franchise encompasses more than 60 active biopharma partnerships, including multiple clinical-stage intracranial programs with expedited FDA review designations. Additionally, the integration of the IRRAflow portfolio is expected to drive cost synergies in the second half of 2026, with management targeting cash neutrality from the IRRAS acquisition by full-year 2027.
Regulatory risk tied to partner programs remains the largest obstacle. In early 2026, B. Riley cut its price target from $28 to $18 after the FDA initially rejected using Phase I/II external-control data for AMT-130 and recommended a randomized Phase III trial, before later reversing course. This episode underscores how quickly sentiment can shift when partner regulatory outcomes disappoint. The company's persistent unprofitability is another headwind: with a negative net margin exceeding 70% and quarterly EPS consistently missing consensus estimates, ClearPoint Neuro must demonstrate a credible path to breakeven before many institutional investors will commit meaningful capital. Cash burn—approximately $8 million in operating cash outflows during Q1 2026 alone—raises the possibility of future equity dilution. CEO Joseph Burnett's sale of over 26,000 shares at approximately $27 per share in October 2025 may also give some investors pause about management's near-term confidence.
The analyst community maintains an overwhelmingly bullish posture on ClearPoint Neuro, with all three active covering firms rating the stock a Buy or Strong Buy. Lake Street's Frank Takkinen reiterated a Buy rating and a $30 target in June 2026. B. Riley's Anderson Schock raised the firm's target to $30 from $20 that same month, citing the AMT-130 accelerated approval pathway as a transformative opportunity. Stifel raised its target to $25 from $16, reflecting updated DCF assumptions incorporating higher modeled revenue growth and improved long-term margin expectations. The average 12-month price target across all three analysts sits at $28.33, implying potential upside of approximately 94% from the most recent closing price. However, one independent rating service, Weiss Ratings, continues to assign a Sell rating, highlighting the divergence of opinion around this speculative growth name.
ClearPoint Neuro's stock chart reveals significant volatility, with the 52-week range spanning from $8.27 to $30.10. A critical resistance zone sits near $20, a level that previously represented analyst support targets before being breached during the stock's steep correction. Any sustainable move toward $25 would likely require the stock to first reclaim $20 and hold above it on increasing volume. On the downside, support near the $14 area has held during the most recent pullback, with stronger support around $10 and the 52-week low of $8.27 representing a worst-case floor. The $25 target aligns closely with a prior consolidation zone from mid-2025 and also corresponds to Stifel's formal price objective, giving it both technical and fundamental significance.
Navigating a volatile growth story like ClearPoint Neuro requires timely and data-driven decision-making. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating actionable Buy, Sell, or Hold signals based on evolving market conditions, technical patterns, and AI-driven analysis. Traders can use these signals to identify emerging opportunities, stay ahead of shifting trends, and manage existing positions with greater confidence and efficiency. For those tracking CLPT or similar high-growth medical device names, AI-powered signals offer an additional layer of insight beyond conventional research.
The $25 price target for ClearPoint Neuro is ambitious but grounded in tangible catalysts that could materialize over the next 12 to 18 months. The FDA-supported accelerated approval pathway for uniQure's AMT-130, combined with a diversified base of more than 60 biopharma partners, provides a credible foundation for significant revenue acceleration and multiple expansion. However, the stock's path to $25 is far from guaranteed. Persistent GAAP losses, quarterly earnings misses, ongoing cash burn, and the ever-present risk of unfavorable regulatory outcomes for partner programs create meaningful downside risk. Investors monitoring CLPT should pay close attention to the AMT-130 BLA filing timeline, quarterly revenue growth trajectory, gross margin trends, and any signs that the company is reducing its cash consumption rate. A successful BLA acceptance and sustained quarterly revenue above $13 million to $14 million would likely be necessary prerequisites for the stock to mount a credible challenge of the $25 level.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CLPT has been loosely correlated with ICUI. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if CLPT jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To CLPT | 1D Price Change % | ||
|---|---|---|---|---|
| CLPT | 100% | +2.47% | ||
| ICUI - CLPT | 57% Loosely correlated | +0.08% | ||
| ISRG - CLPT | 46% Loosely correlated | +0.10% | ||
| A - CLPT | 45% Loosely correlated | -0.25% | ||
| NVST - CLPT | 45% Loosely correlated | -1.69% | ||
| BLFS - CLPT | 44% Loosely correlated | -1.14% | ||
More | ||||
| Ticker / NAME | Correlation To CLPT | 1D Price Change % |
|---|---|---|
| CLPT | 100% | +2.47% |
| Medical/Nursing Services industry (140 stocks) | -28% Poorly correlated | -1.20% |
| Health Services industry (245 stocks) | -33% Poorly correlated | -0.79% |